Komori
Nihon Trim (6788) · FactFirst stated

Revenue and profit growth in the healthcare-related business in FY2022 Q3

First written in FY2022-Q3. . Latest entry: FY2022-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Higher revenue and profit in the medical-related business driven by increased sales at ステムセル研究所A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3First statedAnnual report

    「As a result, the Medical business reported revenue of ¥1,412 million, up 13.6% year on year, and segment profit of ¥126 million, up 48.5%.」

    The Medical business posted higher revenue and profit, driven in part by increased sales at Stem Cell Research Institute.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Nihon Trim yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Revenue and profit growth in the healthcare-related business in FY2022 Q3 | NIHON TRIM CO.,LTD. (6788) | Komori